Liver cancer jaundice of 380umol/L is a complication in the late stage, but it can not be used as a basis for survival judgment, and it can only be said that most of the patients have a 1-year survival rate of less than 10%. Jaundice can be seen in hepatocellular carcinoma due to massive destruction of liver cells or invasion of bile ducts by tumor cells, which is a more common condition in advanced stage of hepatocellular carcinoma patients. However, the survival time of advanced liver cancer patients will be affected by various factors such as treatment plan, physical condition, etc. There is no way to determine the survival time from jaundice 380umol/L alone, only to say that clinically most of the advanced liver cancer patients’ 1-year survival rate is below 10%, which is still a serious situation. If jaundice occurs in liver cancer patients, they should take targeted treatment under the guidance of doctors in time.